American Association for Cancer Research
ccr-22-2177_supplementary_table_1_suppts1.pdf (64.99 kB)

Supplementary Table 1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer

Download (64.99 kB)
journal contribution
posted on 2024-04-03, 21:20 authored by Andrew A. Davis, Jingqin Luo, Tiantian Zheng, Chao Dai, Xiaoxi Dong, Lu Tan, Rama Suresh, Foluso O. Ademuyiwa, Caron Rigden, Timothy P. Rearden, Katherine Clifton, Katherine Weilbaecher, Ashley Frith, Pavan K. Tandra, Tracy Summa, Brittney Haas, Shana Thomas, Leonel F. Hernandez-Aya, Lindsay L. Peterson, Xiaohong Wang, Shujun J. Luo, Kemin Zhou, Pan Du, Shidong Jia, Bonnie L. King, Jairam Krishnamurthy, Cynthia X. Ma

PredicineATLAS gene panel.



Clinical biomarkers to identify patients unlikely to benefit from CDK4/6 inhibition (CDK4/6i) in combination with endocrine therapy (ET) are lacking. We implemented a comprehensive circulating tumor DNA (ctDNA) analysis to identify genomic features for predicting and monitoring treatment resistance. ctDNA was isolated from 216 plasma samples collected from 51 patients with hormone receptor–positive (HR+)/HER2-negative (HER2−) metastatic breast cancer (MBC) on a phase II trial of palbociclib combined with letrozole or fulvestrant (NCT03007979). Boosted whole-exome sequencing (WES) was performed at baseline and clinical progression to evaluate genomic alterations, mutational signatures, and blood tumor mutational burden (bTMB). Low-pass whole-genome sequencing was performed at baseline and serial timepoints to assess blood copy-number burden (bCNB). High bTMB and bCNB were associated with lack of clinical benefit and significantly shorter progression-free survival (PFS) compared with patients with low bTMB or low bCNB (all P < 0.05). Dominant APOBEC signatures were detected at baseline exclusively in cases with high bTMB (5/13, 38.5%) versus low bTMB (0/37, 0%; P = 0.0006). Alterations in ESR1 were enriched in samples with high bTMB (P = 0.0005). There was a high correlation between bTMB determined by WES and bTMB determined using a 600-gene panel (R = 0.98). During serial monitoring, an increase in bCNB score preceded radiographic progression in 12 of 18 (66.7%) patients. Genomic complexity detected by noninvasive profiling of bTMB and bCNB predicted poor outcomes in patients treated with ET and CDK4/6i and identified early disease progression before imaging. Novel treatment strategies including immunotherapy-based combinations should be investigated in this population.

Usage metrics

    Clinical Cancer Research





    Ref. manager